EA200601217A1 - Новые конденсированные пирролокарбазолы - Google Patents

Новые конденсированные пирролокарбазолы

Info

Publication number
EA200601217A1
EA200601217A1 EA200601217A EA200601217A EA200601217A1 EA 200601217 A1 EA200601217 A1 EA 200601217A1 EA 200601217 A EA200601217 A EA 200601217A EA 200601217 A EA200601217 A EA 200601217A EA 200601217 A1 EA200601217 A1 EA 200601217A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyrrocarbazoles
new condensed
methods
present
condensed
Prior art date
Application number
EA200601217A
Other languages
English (en)
Other versions
EA012295B1 (ru
Inventor
Надин К. Бекнэлл
Джеймс Л. Дайболд
Дайан Э. Джингрич
Роберт Л. Хадкинз
Данду Р. Редди
Мин Тао
Теодор Л. Андерайнер
Эллисон Л. Зулли
Original Assignee
Сефалон, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сефалон, Инк. filed Critical Сефалон, Инк.
Publication of EA200601217A1 publication Critical patent/EA200601217A1/ru
Publication of EA012295B1 publication Critical patent/EA012295B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Abstract

Настоящее изобретение в общем относится к выбранным конденсированным пирролокарбазолам, в том числе их фармацевтическим композициям и способам лечения заболеваний. Настоящее изобретение также относится к промежуточным продуктам и способам получения заявленных конденсированных пирролокарбазолов.
EA200601217A 2003-12-23 2004-12-23 Конденсированные пирролокарбазолы EA012295B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53218203P 2003-12-23 2003-12-23
US11/017,947 US7169802B2 (en) 2003-12-23 2004-12-22 Fused pyrrolocarbazoles
PCT/US2004/043160 WO2005063763A1 (en) 2003-12-23 2004-12-23 Novel fused pyrrolocarbazoles

Publications (2)

Publication Number Publication Date
EA200601217A1 true EA200601217A1 (ru) 2006-12-29
EA012295B1 EA012295B1 (ru) 2009-08-28

Family

ID=34703676

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601217A EA012295B1 (ru) 2003-12-23 2004-12-23 Конденсированные пирролокарбазолы

Country Status (30)

Country Link
US (4) US7169802B2 (ru)
EP (1) EP1704148B1 (ru)
JP (1) JP5006046B2 (ru)
KR (2) KR101179372B1 (ru)
CN (1) CN1918162B (ru)
AR (1) AR047168A1 (ru)
AT (1) ATE500256T1 (ru)
AU (1) AU2004309394B2 (ru)
BR (1) BRPI0418113B8 (ru)
CA (1) CA2549627C (ru)
CR (1) CR8519A (ru)
CY (1) CY1111524T1 (ru)
DE (1) DE602004031672D1 (ru)
DK (1) DK1704148T3 (ru)
EA (1) EA012295B1 (ru)
HK (1) HK1096096A1 (ru)
HR (1) HRP20110373T1 (ru)
IL (1) IL176384A (ru)
IS (1) IS8519A (ru)
MA (1) MA28298A1 (ru)
MY (2) MY143373A (ru)
NO (2) NO336893B1 (ru)
NZ (1) NZ548099A (ru)
PL (1) PL1704148T3 (ru)
PT (1) PT1704148E (ru)
RS (1) RS51886B (ru)
SG (1) SG149045A1 (ru)
SI (1) SI1704148T1 (ru)
TW (1) TWI355385B (ru)
WO (1) WO2005063763A1 (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276497A1 (en) * 2000-05-09 2006-12-07 Cephalon, Inc. Novel multicyclic compounds and the use thereof
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
US20090270511A1 (en) * 2006-09-08 2009-10-29 Merck Frosst Canada Ltd. Prodrugs of inhibitors of cathepsin s
US20080125377A1 (en) * 2006-11-28 2008-05-29 Bartels Stephen P Delivery system for antiangiogenic and antiinflammatory pharmaceuticals and method of use
EP2167075A4 (en) * 2007-06-08 2012-07-11 Univ Massachusetts MIXED LINEAGE KINASES AND METABOLISM DISORDER
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
UA107652C2 (en) 2008-10-06 2015-02-10 Incuron Llc Carbazole compounds and therapeutic uses of the compounds
KR20110081862A (ko) 2008-10-22 2011-07-14 제넨테크, 인크. 축삭 변성의 조절
CN104016992B (zh) * 2008-11-19 2017-04-12 赛福伦公司 吲唑并[5,4‑a]吡咯并[3,4‑c]咔唑化合物的形式
EP2192121A1 (en) 2008-11-27 2010-06-02 Cephalon France Regioselective reduction of fused pyrrolocarbazoles-5,7-diones
WO2010078421A1 (en) * 2008-12-30 2010-07-08 Arqule, Inc. Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds
WO2010078427A1 (en) * 2008-12-30 2010-07-08 Arqule, Inc. Substituted pyrazolo [3, 4-b] pyridine compounds
MX2012004638A (es) * 2009-10-22 2012-07-04 Genentech Inc Modulacion de degeneracion de axones.
US20110189174A1 (en) * 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
AU2011256264B2 (en) 2010-05-18 2016-09-15 Cephalon, Inc. Method for purifying a fused pyrrolocarbazole derivative
CN103664797A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
CN104370880A (zh) * 2013-01-24 2015-02-25 韩冰 一类蛋白酶抑制剂及其制备方法和用途
CN104981697B (zh) 2013-02-11 2017-08-04 英丘伦有限责任公司 促染色质转录复合物(fact)在癌症中的用途
EP3049077A4 (en) * 2013-09-26 2017-02-15 CHDI Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA033925B1 (ru) 2014-04-06 2019-12-10 Общество С Ограниченной Ответственностью "Инкурон" Комбинированная терапия гепатоцеллюлярной карциномы

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ245203A (en) 1991-11-29 1997-07-27 Banyu Pharma Co Ltd 5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione derivatives substituted in position-13 by a pentose or hexose group; corresponding indolo-furano(anhydride)intermediates
US5594009A (en) * 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5591855A (en) * 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5705511A (en) 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
ES2169414T3 (es) 1996-08-22 2002-07-01 Bristol Myers Squibb Co Amino-azucar citotoxico y derivados de azucares relacionados de indolopirrolocarbazoles.
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
US6630500B2 (en) 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
PT1325011E (pt) * 2000-09-29 2004-09-30 Lilly Co Eli Metodos e compostos para tratamento de doencas proliferativas
US6653290B2 (en) 2000-10-06 2003-11-25 Bristol-Myers Squibb Company Tumor proliferation inhibitors
US6610727B2 (en) 2000-10-06 2003-08-26 Bristol-Myers Squibb Company Anhydro sugar derivatives of indolocarbazoles
US7018999B2 (en) 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles

Also Published As

Publication number Publication date
IL176384A0 (en) 2006-10-05
TWI355385B (en) 2012-01-01
CA2549627A1 (en) 2005-07-14
CN1918162A (zh) 2007-02-21
DE602004031672D1 (de) 2011-04-14
EP1704148B1 (en) 2011-03-02
US20100152196A1 (en) 2010-06-17
AU2004309394A1 (en) 2005-07-14
NO20063196L (no) 2006-09-20
BRPI0418113B8 (pt) 2021-05-25
EP1704148A1 (en) 2006-09-27
US7169802B2 (en) 2007-01-30
HRP20110373T1 (hr) 2011-06-30
KR20120066057A (ko) 2012-06-21
TW200530243A (en) 2005-09-16
IS8519A (is) 2006-06-22
JP5006046B2 (ja) 2012-08-22
US8383813B2 (en) 2013-02-26
US20050143442A1 (en) 2005-06-30
US8044064B2 (en) 2011-10-25
SI1704148T1 (sl) 2011-06-30
AU2004309394B2 (en) 2011-04-28
WO2005063763A1 (en) 2005-07-14
NO336893B1 (no) 2015-11-23
PT1704148E (pt) 2011-05-25
IL176384A (en) 2015-05-31
EA012295B1 (ru) 2009-08-28
RS51886B (en) 2012-02-29
PL1704148T3 (pl) 2011-07-29
US20120004253A1 (en) 2012-01-05
US20060247294A1 (en) 2006-11-02
BRPI0418113A (pt) 2007-04-17
US7671064B2 (en) 2010-03-02
DK1704148T3 (da) 2011-06-14
CY1111524T1 (el) 2015-08-05
SG149045A1 (en) 2009-01-29
MY158159A (en) 2016-09-15
CA2549627C (en) 2012-12-11
ATE500256T1 (de) 2011-03-15
CN1918162B (zh) 2014-05-14
HK1096096A1 (en) 2007-05-25
CR8519A (es) 2007-06-06
MA28298A1 (fr) 2006-11-01
NO20151245A1 (no) 2015-09-23
MY143373A (en) 2011-04-29
AR047168A1 (es) 2006-01-11
KR20060127069A (ko) 2006-12-11
KR101179372B1 (ko) 2012-09-03
BRPI0418113B1 (pt) 2020-04-14
NZ548099A (en) 2010-05-28
JP2007516293A (ja) 2007-06-21

Similar Documents

Publication Publication Date Title
NO20063193L (no) Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav
EA200601217A1 (ru) Новые конденсированные пирролокарбазолы
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
EA200501430A1 (ru) Лиганды каннабиноидных рецепторов и их применение
CY1109104T1 (el) 1,2,3,4 τετρα-υποκατεστημενη ινδολη για την αντιμετωπιση ασθενειων του αναπνευστικου
ATE362932T1 (de) Azaindolverbindungen als kinaseinhibitoren
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
SE0101675D0 (sv) Novel composition
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
EA200500169A1 (ru) Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение
SE0202241D0 (sv) Novel Compounds
TW200740844A (en) Novel MAdCAM antibodies
SE0301010D0 (sv) Novel compounds
DK1353672T3 (da) Syntese af 4-amino-thalidomidenantiomerer
EA200802213A1 (ru) Способы лечения заболеваний крови
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
EA200301213A1 (ru) Лиганды рецепторов 5-ht и их применение
SE0301009D0 (sv) Novel compounds
SE0301653D0 (sv) Novel compounds
EA200201214A1 (ru) Замещенные тиоацетамиды
TW200509892A (en) Novel aminobenzophenone compounds
EA200600735A1 (ru) Нуклеиновые кислоты, специфично связывающие биоактивный грелин
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU